On Wednesday, BofA Securities adjusted its outlook on HealthEquity, Inc (NASDAQ: HQY), reducing the price target to $100 from the previous $105, while maintaining a Buy rating on the stock. The reassessment comes as the firm acknowledges the company's potential for faster organic growth and benefits from strategic mergers and acquisitions. The company's operating leverage is seen as a key factor supporting this view, with rising interest rates being a significant contributor to this leverage so far.
HealthEquity's investments in generative AI technology are expected to control service cost growth, and its Technology & Development spending is predicted to stabilize as a percentage of revenue. These factors are anticipated to continue driving the company's operating leverage. Despite a guidance raise that was more conservative than expected, given the robustness of the quarter, BofA Securities remains confident in HealthEquity's performance for the second half of the year.
Previously in March 2023, BofA Securities projected that HealthEquity could achieve over $500 million in FY25 EBITDA in an optimistic scenario. The firm upholds this projection, citing HealthEquity's solid operating model within the healthcare IT sector. The new price target of $100 reflects approximately 18 times the projected CY25 enterprise value to EBITDA (EV/EBITDA), a roll-forward from the 21.5 times CY24 EBITDA previously estimated. The adjustment in the multiple also takes into account the compression of multiples within the peer group.
In other recent news, HealthEquity Inc. saw a promising Q2, with revenues reaching $299.9 million, a 23% increase from the previous year. This surpassed both BTIG's and consensus estimates, which were $276.9 million and $285 million, respectively. The company's adjusted EBITDA also saw a significant increase, reaching $128.3 million, a 46% increase from the previous year.
Following these strong results, BTIG upgraded HealthEquity's stock target to $110, reiterating a Buy rating. In response to the robust quarter, HealthEquity revised its full-year guidance for fiscal 2025 upwards for both revenue and adjusted EBITDA. The company also experienced a 15% growth in Health Savings Account memberships, with assets swelling by 27% and total accounts rising by 9%.
HealthEquity also reported adjusted earnings of $0.86 per share, exceeding the projected $0.70 per share. Looking ahead, the company has revised its earnings forecast for fiscal 2025 to $2.98-$3.14 per share, up from the previous $2.48-$2.66. Lastly, HealthEquity announced a $300 million share repurchase program, demonstrating confidence in its financial position and growth trajectory.
InvestingPro Insights
InvestingPro data and insights provide a more nuanced view of HealthEquity, Inc's (NASDAQ: HQY) financial health and market position. With a market capitalization of $6.84 billion and a high P/E ratio of 84.29, reflecting investor confidence in future earnings growth, HealthEquity appears to be trading at premium valuation multiples. The company's revenue growth over the last twelve months is notable at 15.8%, indicating a strong upward trajectory in its financial performance.
Two InvestingPro Tips highlight the positive sentiment around HealthEquity: Analysts have revised their earnings upwards for the upcoming period, and the company is expected to grow its net income this year. These insights suggest that the market anticipates HealthEquity to continue its profitability streak, which is also supported by its high return over the last decade. Additionally, HealthEquity's liquid assets exceed short-term obligations, indicating a solid liquidity position that could support ongoing operations and strategic initiatives.
For readers seeking a deeper analysis, InvestingPro offers more tips on HealthEquity, providing a comprehensive understanding of the company's financial nuances and market prospects. These additional tips are available at https://www.investing.com/pro/HQY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.